
New chief executive for Medivir
pharmafile | August 14, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Medivir, Niklas Prager
Niklas Prager has been named as the new president and chief executive of Sweden-based pharma firm Medivir.
Starting in September, Prager has been on Medivir’s board since May and is to replace Maris Hartmanis who is leaving the company.
Prager’s previous roles include working for Merck both in the US and Sweden, and serving as the chief executive in Sweden for Pfizer, Envirotainer and Qbtech.
“I am delighted to welcome Niklas to the position of chief executive of Medivir,” says Birgitta Stymne Göransson, chairman of the board of directors of Medivir. “Niklas has a background in both biotech and big pharma, and his large network of contacts in the Swedish and international pharmaceutical industries make him an ideal choice for us.”
Prager adds: “Together with the board, the highly skilled research team and all other Medivir employees, I will be focussing on further value creation and enhanced visibility of Medivir’s potential.”
Related Content
Cancer Research Technology and Medivir to develop new class of cancer drugs
Cancer Research Technology and Medivir will join forces to develop a new class of drugs …

Twitter ‘drama’ produces drubbing for Medivir
A NASDAQ disciplinary committee has found Medivir guilty of breaching its rules after data from …

Medivir and Janssen in dengue fever research alliance
Medivir, the speciality pharma company focused on infectious diseases, it to collaborate with Janssen on …






